Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Pau Montesinos, Lorenzo Algarra et al.|Blood Advances|2021Cited by 25
Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemiaCatia Simoes, Patrik Fazio, Carmen González et al.|Blood Neoplasia|2024Cited by 2
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?Edwin Uriel Suárez, Blanca Boluda, Esperanza Lavilla et al.|Annals of Hematology|2024Cited by 1